Skip to results
Modify your search
NARROW
1-20 of 218
Section: Lung cancer
Journal Article
Emerging molecular testing paradigms in non-small cell lung cancer management—current perspectives and recommendations
The Oncologist, Volume 30, Issue 3, March 2025, oyae357, https://doi.org/10.1093/oncolo/oyae357
Published: 24 March 2025
Journal Article
Aumolertinib plus chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R: a phase II trial
The Oncologist, Volume 30, Issue 3, March 2025, oyae336, https://doi.org/10.1093/oncolo/oyae336
Published: 15 March 2025
Journal Article
Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients (CLICaP)
The Oncologist, Volume 30, Issue 2, February 2025, oyae347, https://doi.org/10.1093/oncolo/oyae347
Published: 28 February 2025
Journal Article
Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis
The Oncologist, Volume 30, Issue 2, February 2025, oyae344, https://doi.org/10.1093/oncolo/oyae344
Published: 25 February 2025
Journal Article
Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer
The Oncologist, Volume 30, Issue 1, January 2025, oyae356, https://doi.org/10.1093/oncolo/oyae356
Published: 23 January 2025
Journal Article
The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients
The Oncologist, Volume 30, Issue 3, March 2025, oyae279, https://doi.org/10.1093/oncolo/oyae279
Published: 27 November 2024
Journal Article
Long-term safety of selpercatinib for Rearranged during transfection (RET)-activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time
The Oncologist, Volume 29, Issue 12, December 2024, Pages 1068–1078, https://doi.org/10.1093/oncolo/oyae282
Published: 29 October 2024
Journal Article
Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer
The Oncologist, Volume 29, Issue 12, December 2024, Pages 1079–1089, https://doi.org/10.1093/oncolo/oyae234
Published: 30 September 2024
Journal Article
The association of azole antifungals with overall survival in patients with non-small cell lung cancer receiving immune checkpoint inhibitors
The Oncologist, Volume 30, Issue 2, February 2025, oyae262, https://doi.org/10.1093/oncolo/oyae262
Published: 25 September 2024
Journal Article
Proceedings of the 1st biannual bridging the gaps in lung cancer conference
The Oncologist, Volume 30, Issue 2, February 2025, oyae228, https://doi.org/10.1093/oncolo/oyae228
Published: 05 September 2024
Journal Article
Advances and future directions in ROS1 fusion-positive lung cancer
The Oncologist, Volume 29, Issue 11, November 2024, Pages 943–956, https://doi.org/10.1093/oncolo/oyae205
Published: 23 August 2024
Journal Article
Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations
The Oncologist, Volume 29, Issue 10, October 2024, Pages 833–841, https://doi.org/10.1093/oncolo/oyae091
Published: 22 June 2024
Journal Article
Investigating risk factors and treatment options for severe, partially steroid responsive, and steroid-refractory checkpoint inhibitor pneumonitis
The Oncologist, Volume 29, Issue 11, November 2024, Pages e1575–e1585, https://doi.org/10.1093/oncolo/oyae147
Published: 17 June 2024
Journal Article
The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC
The Oncologist, Volume 29, Issue 7, July 2024, Pages 609–618, https://doi.org/10.1093/oncolo/oyae107
Published: 18 May 2024
Journal Article
Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer
The Oncologist, Volume 29, Issue 7, July 2024, Pages e932–e940, https://doi.org/10.1093/oncolo/oyae052
Published: 25 March 2024
Journal Article
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World
The Oncologist, Volume 29, Issue 7, July 2024, Pages 596–608, https://doi.org/10.1093/oncolo/oyae043
Published: 23 March 2024
Journal Article
Single-Cell Sequencing Illuminates Thymic Development: An Updated Framework for Understanding Thymic Epithelial Tumors
The Oncologist, Volume 29, Issue 6, June 2024, Pages 473–483, https://doi.org/10.1093/oncolo/oyae046
Published: 23 March 2024
Journal Article
Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer With Actionable Driver Oncogenes
The Oncologist, Volume 29, Issue 6, June 2024, Pages 534–542, https://doi.org/10.1093/oncolo/oyae022
Published: 28 February 2024
Journal Article
Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial
The Oncologist, Volume 29, Issue 5, May 2024, Pages e690–e698, https://doi.org/10.1093/oncolo/oyad342
Published: 20 February 2024
Journal Article
Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials Get access
The Oncologist, Volume 29, Issue 5, May 2024, Pages 422–430, https://doi.org/10.1093/oncolo/oyae006
Published: 13 February 2024
